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ABSTRACT: The molecular processes of aging are very heterogenic and not fully understood. Studies on rare 
progeria syndromes, which display an accelerated progression of physiological aging, can help to get a better 
understanding. Pseudoxanthoma elasticum (PXE) caused by mutations in the ATP-binding cassette sub-family C 
member 6 (ABCC6) gene shares some molecular characteristics with such premature aging diseases. Thus, this is 
the first study trying to broaden the knowledge of aging processes in PXE patients. In this study, we investigated 
aging associated biomarkers in primary human dermal fibroblasts and sera from PXE patients compared to 
healthy controls. Determination of serum concentrations of the aging biomarkers eotaxin-1 (CCL11), growth 
differentiation factor 11 (GDF11) and insulin-like growth factor 1 (IGF1) showed no significant differences 
between PXE patients and healthy controls. Insulin-like growth factor binding protein 3 (IGFBP3) showed a 
significant increase in serum concentrations of PXE patients older than 45 years compared to the appropriate 
control group. Tissue specific gene expression of GDF11 and IGFBP3 were significantly decreased in fibroblasts 
from PXE patients compared to normal human dermal fibroblasts (NHDF). IGFBP3 protein concentration in 
supernatants of fibroblasts from PXE patients were decreased compared to NHDF but did not reach statistical 
significance due to potential gender specific variations. The minor changes in concentration of circulating aging 
biomarkers in sera of PXE patients and the significant aberrant tissue specific expression seen for selected factors 
in PXE fibroblasts, suggests a link between ABCC6 deficiency and accelerated aging processes in affected 
peripheral tissues of PXE patients.    
 







Aging is a heterogeneous process which is characterized 
by a time-dependent decline of physiological 
functionality and integrity. Thus, as an organism ages, it 
gets progressively vulnerable to various pathologies like 
cancer, diabetes as well as cardiovascular and 
neurodegenerative diseases ultimately leading to death 
(reviewed in [1]).  
Due to the complexity of aging, finding appropriate 
study models is still a problem. In many cases rare 
progeria syndromes like the Hutchinson-Gilford-progeria 
syndrome (HGPS) or related cell culture models 
displaying an accelerated aging process are used for 
gerontological studies [2-4]. As one single model cannot 
provide an entire description of potential physiological 
  Volume 11, Number 3; 536-546, June 2020                       
 Tiemann J., et al                                                                                      Linking ABCC6 deficiency to premature aging 
 
Aging and Disease • Volume 11, Number 3, June 2020                                                                              537 
 
aging processes, the need for further models is steadily of 
great interest.  
Pseudoxanthoma elasticum (PXE) is a rare inherited 
genetic disorder caused by mutations in the ATP-binding 
cassette subfamily C member 6 (ABCC6) gene which 
causes a deficiency of the encoded transporter protein [5, 
6]. In the general population the prevalence of PXE is 
supposed to be between 1:25 000 and 1:100 000. Females 
seem to be affected more often than males for yet 
unknown reasons (summarized in [7]). Thusfar, the 
molecular characteristics of PXE have only barely been 
discussed or interpreted in the light of premature aging 
processes although patients display clinical and molecular 
characteristics of premature aging and known premature 
aging syndromes. PXE patients display soft tissue 
calcification affecting the skin, eyes and the 
cardiovascular system. It primarily leads to the 
fragmentation of elastic fibers and remodeling of the 
extracellular matrix resulting in a premature loss of skin 
elasticity, extensive wrinkle formation, arteriosclerosis 
and visual impairment with similarities to macular 
degeneration, all of which are clinical characteristics of 
the elderly (summarized in [7, 8]). Molecular studies 
showed that ABCC6 deficiency leads to aberrant 
pyrophosphate homeostasis, a known calcification 
inhibitor, characterized by a decreased plasma 
concentration [9-12]. Similar observations were made in 
patients suffering from the premature aging syndrome 
HGPS [13]. It was further shown that the progression of 
HGPS can be decelerated by administration of statins and 
bisphosphonates [3]. Studies demonstrated that this 
therapy could be also beneficial for PXE although the 
underlying molecular mechanisms remain unclear [14-
16]. 
Additionally, it was shown that ABCC6 deficiency 
leads to an aberrant mitochondrial function and a loss of 
proteostasis characterized by abnormal expression and 
serum concentrations of matrix metalloproteinases [17, 
18]. Both, mitochondrial dysfunction and a loss of 
proteostasis are known to play a role in physiological 
aging [19-21].  
Additionally, studies showed that blood from young 
mice have rejuvenating effects in old mice, demonstrating 
that specific blood factors need to change concentrations 
during the course of aging [22-24]. Similar assumptions 
could be made for PXE pathogenesis as parabiosis 
experiments with Abcc6-/-/ Rag-/- and wild-type mice 
resulted in a prevention of further ectopic mineralization 
in Abcc6-/-/ Rag-/- mice [25]. Furthermore, it was shown 
that normal human fibroblasts form abnormal elastic fiber 
aggregates when cultured with serum from PXE patients 
[26].   
To gain insight into potential blood factors involved 
in PXE pathogenesis, the investigation of aging processes 
in PXE patients by determination of biomarkers showing 
clear association with aging could be helpful. Changes in 
concentration of proteins like growth differentiation 
factor 11 (GDF11), eotaxin-1 (CCL11), insulin-like 
growth factor 1 (IGF1) and its binding protein insulin-like 
growth factor binding protein 3 (IGFBP3) were associated 
with aging processes [24, 27-30]. By analyzing these 
aging biomarkers in sera and fibroblasts of PXE patients, 
we could show aberrant mRNA and protein expression in 
supernatants of PXE fibroblasts as well as abnormal 
serum concentrations of specific aging biomarkers in PXE 
patients underlining the suggestion of potential premature 
aging processes. With this, we were able to give first 
evidence for a link between an ABCC6 deficiency and 
accelerated aging processes especially in affected 
peripheral tissues of PXE patients.    
 




The study was approved by the ethics commission of the 
Ruhr University of Bochum Faculty of Medicine, located 
in Bad Oeynhausen. Patients participating in the study 
gave their written informed consent. 
The goal of the study was to investigate known aging 
biomarker in PXE sera to evaluate whether potential 
premature aging processes contribute to PXE 
pathogenesis. Because little is known about aging 
processes of PXE patients, some of the most prominent 
serum proteins with clear connection to aging (CCL11, 
GDF11, IGF1 and IGFBP3) were chosen to get first 
insights [24, 27-30]. In case of ambiguous results or 
aberrant serum concentrations in PXE patients compared 
to controls additional mRNA analysis in fibroblasts and 
protein determination in cell culture supernatants was 




In all patients the diagnosis of PXE was consistent with 
the consensus criteria reported [31]. Age/sex-matched 
blood donors served in this study as healthy controls. For 
analysis, each cohort was divided into subgroups 
composed of patients and healthy controls under 45 years 
and subgroups composed of patients and healthy controls 
over 45 years. The subgroups including patients and 
healthy controls under 45 years consisted of 18 female 
[mean ± SD age, 31.9 ± 7.86 years] and 5 male 
[39.6 ± 4.51 years] PXE patients as well as 18 female 
[32.0 ± 7.87 years] and 5 male [39.8 ± 4.60 years] blood 
donors as healthy controls. The subgroups including 
patients and healthy controls over 45 years consisted of 14 
female [55.0 ± 8.20 years] and 8 male [54.6 ± 9.38 years] 
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PXE patients as well as 14 female [54.5 ± 6.65 years] and 





Normal human dermal fibroblasts (NHDF) from healthy 
controls were purchased from Coriell Institute for 
Medical Research (Camden, USA). Dermal fibroblasts 
from PXE patients were isolated from skin biopsies [32]. 
A summary of fibroblast characteristics used can be 
additionally found in Table 1.  
For cultivation, Dulbecco’s modified essential 
medium (DMEM, Gibco, Invitrogen, Germany) 
containing 10% fetal calf serum (FCS; Biowest,  
Aidenbach, Germany), 2% L-glutamine (200mM) (PAN 
Biotech, Eidenach, Germany) and 1% antibiotic/ 
antimycotic solution (PAA Laboratories, Pasching, 
Austria) was used. Cells were subcultured as they reached 
confluency. 
For experiments cells between passage 9 and 12 were 
used. Biological samples were performed in triplicates for 
all experiments. Cells were seeded with a final density of 
177 cells/ mm2 using 60 mm culture dishes (BD Falcon) 
and cultivated for 24 h in 10% FCS. After this, cells were 
washed with phosphate-buffered saline (PBS; Gibco, 
Invitrogen, Germany) and medium was replaced with 
fresh 10% FCS. Medium was changed every 3-4 d and 
cells were cultured for 21 d. 
 
Table 1. Characterization of human dermal fibroblasts from PXE patients and healthy controls. 
 
Sample ID Gender Age1 Biopsy source  ABCC6 genotype2 Genotype status 
PXE patients 
P3M a male 57 Neck c.3421C>T (p.R1141X) c.3883-6G>A (SSM) cht 









male 57 Arm - - wt 
M52A b 
(AG11482) 
male 52 Arm - - wt 
F48A b 
(AG14284) 
female 48 Arm - - wt 
 
hm, homozygote; cht, compound heterozygote; ht, heterozygote; wt, wild type; SSM, splice site mutation. 
a 
Fibroblasts isolated from skin biopsies [32] 
. 
b 
Fibroblasts purchased from Coriell Institute for Medical Research (Camden, USA). 
1
Age in years. 
2
Nucleotide numbering refers to the cDNA 
sequence with the A of the ATG translation initiation start site as nucleotide +1 (GenBank accession number NM_001171.2). 
 
Nucleic acid isolation 
 
RNA isolation was performed using the NucleoSpin RNA 
Kit (Macherey-Nagel, Düren, Germany), according to the 
manufacturer’s instructions. For DNA isolation, a 50 µl 
aliquot was collected after the first column based cleanup 
step. DNA isolation was performed using NucleoSpin 
Blood extraction Kit (Macherey-Nagel, Düren, 
Germany). DNA concentrations were used to normalize 
ELISA measurement data of cell culture supernatants to 
the number of cells during culture. 
 
Gene expression analysis 
 
RNA was isolated as previously described. 1 µg RNA was 
transcribed to cDNA using SuperScript II Reverse 
Transcriptase (Thermo Fisher Scientific, San Diego, 
USA). For final measurements 2.5 µl cDNA (1:10), 0.25 
µl forward and reverse primer (Biomers, Ulm, Germany), 
2.0 µl water and 5.0 µl LightCycler 480 SYBR Green I 
Master reaction mixture (Roche, Penzberg, Germany) was 
mixed. After incubation for 5 min at 95°C, gene 
expression was determined by performing 45 cycles of 
denaturation (95°C, 10 s), annealing (specific annealing 
temperature, 15 s) and elongation (72°C, 20 s). Thereafter 
melting curve analysis was done. Quantitative real-time 
PCR (qPCR) was performed using LightCycler 480 
(Roche, Penzberg, Germany) under conditions described 
in Table 2. As IGFBP3 and GDF11 showed aberrant or 
ambiguous serum concentrations, relative mRNA 
expression levels were measured and normalized to 
relative β-actin (β-ACTIN), glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) and β2-micro-globulin (β2M) 
mRNA expression. Results were calculated using delta-
delta Ct method considering PCR efficiency. Technical 
triplicates were performed for each biological sample.  
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Quantification of aging biomarker in human sera and 
cell culture supernatants 
 
Concentrations of GDF11, IGF1, IGFBP3 and CCL11 
were measured in sera from 45 PXE patients and sera 
from 45 age /sex-matched healthy controls. For IGF1, 
IGFBP3 and CCL11 Human Quantikine ELISA Kits 
(R&D Systems, Abingdon, UK) were used according to 
manufacturer’s instructions.  
For GDF11 a DuoSet ELISA Development Kit (R&D 
Systems, Abingdon, UK) was used to develop a sandwich 
ELISA. The GDF11 ELISA was basically designed as 
recommended by the manufacturer. GDF11 standard was 
set up in FCS as calibrator diluent. For background 
measurement of standard, the zero standard was used. To 
consider any interfering effects of human sera on the 
antibody reaction, the lowest sample value measured was 
taken as background measurement [33].  
For targets showing ambiguous results (GDF11) or 
aberrant serum concentrations in PXE patients compared 
to controls (IGFBP3) additional mRNA analysis in 
fibroblasts and protein determination in cell culture 
supernatants was performed when possible.  
Measurements of GDF11 in cell culture supernatants 





For qPCR analysis and protein concentrations of 
supernatants, data are shown as means ± standard error 
(SEM). For serum protein concentrations, data are shown 
as Box-Plot with median, 25th and 75th percentile and 
Tukey whiskers (± 1.5 times interquartile range). 
GraphPad Prism 5.0 was used as a statistical software. 
Data distribution was analyzed by Shapiro-Wilk test. For 
results of the measurement of serum concentrations a 
Student’s t-test (unpaired, two-tailed) was performed in 
case of normal distribution. If one of the compared groups 
was not Gaussian distributed the non- parametric two-
tailed Mann-Whitney U test was done. For gene 
expression results and protein concentrations in 
supernatants the non- parametric two-tailed Mann-
Whitney U test was performed. P-values of 0.05 or less 
were considered statistically significant.
 
 
Table 2. Primer sequences used for quantitative real-time PCR.  
 
 
















































insulin-like growth factor 

















Increased serum concentrations of CCL11 in aged 
individuals 
 
As seen in Fig. 1, means of serum concentration of CCL11 
increased significantly with age in PXE patients (<45 
years: 135.4 ± 10.6 pg/ml; >45 years: 207.8 ± 22.9 pg/ml; 
p≤0.01) as well as in healthy controls (<45 years: 158.9 ± 
13.0 pg/ml; >45 years: 231.7 ± 21.8 pg/ml; p≤0.01). No 
significant differences in CCL11 protein concentration 
were seen between PXE patients and healthy controls.  
 
Aberrant serum concentration and decreased gene 
expression of GDF11 in PXE patients 
 
Because of low GDF11 serum concentrations, 20% of 
measured values were outside standard curve and were 
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not included into further data analysis. However, none of 
the findings reached statistical significance due to the high 
variances among individuals (Fig. 2A). 
 
 
Figure 1. CCL11 protein concentration in sera from PXE 
patients (grey) and healthy controls (white). Data are shown 
as Box-Plot with median, 25th and 75th percentile and Tukey 
whiskers (± 1.5 times interquartile range). Control vs. PXE: ns 
p>0.05. Cohorts <45 years (n=23) vs. cohorts >45 years (n=22): 
##/++ p≤0.01.   
 
To further evaluate GDF11 levels in PXE patients, 
mRNA expression analysis was performed. As seen in 
Fig. 2B, GDF11 mRNA expression in PXE fibroblasts 
was significantly decreased compared to age/sex-matched 
NHDF (PXE: 0.53 ± 0.04; control: 0.92 ± 0.04; p≤0.001). 
Determination of GDF11 protein concentrations in 
supernatants was not possible because concentrations 
were below the detection limit. 
 
Altered protein concentration and gene expression of 
IGF1 and IGFBP3 
 
In healthy controls, serum protein concentration of IGF1 
showed a minor decrease with age. This was not seen for 
serum concentrations of IGF1 in PXE patients. However, 
in PXE patients under 45 years slightly lower IGF1 levels 
compared to the appropriate healthy control group were 
observed. None of these results reached statistical 
significance (Fig. 3A). 
For IGFBP3, no significant age dependent changes in 
serum concentrations were seen for PXE patients or for 
healthy controls. However, PXE patients over 45 years 
showed a significant increase in serum IGFBP3 
concentrations compared to appropriate healthy controls 
(PXE: 2543.0 ± 104.9 ng/ml; control: 2117.0 ± 147.6 




Figure 2. Systemic concentration and local mRNA expression of GDF11. (A) GDF11 protein concentration in sera 
from PXE patients (grey) and healthy controls (white). Data are shown as Box-Plot with median, 25th and 75th percentile 
and Tukey whiskers (± 1.5 times interquartile range). (B) Relative GDF11 mRNA-expression of PXE fibroblasts (grey) 
and NHDF (white). Data are shown as mean ± SEM. Control vs. PXE: *** p ≤0.001. Cohorts <45 years (n=23) vs. 
cohorts >45 years (n=22): ns p>0.05.   
Consequently, the molar IGF1/IGFBP3 ratio showed 
no differences with age but a significant decrease in PXE 
patients over 45 years compared to appropriate healthy 
controls (PXE: 0.22 ± 0.01; control: 0.31 ± 0.03; p≤0.05) 
(Fig. 3C).  
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Figure 3. Systemic IGF1 and IGFBP3 protein concentration in sera from PXE patients (grey) and 
healthy controls (white).  (A) IGF1 serum protein concentrations of PXE patients (grey) and healthy 
controls (white) (B) IGFBP3 serum protein concentrations of PXE patients (grey) and healthy controls 
(white) (C) molar IGF1/IGFBP3 ratio of serum protein concentrations of PXE patients (grey) and healthy 
controls (white). Data are shown as Box-Plot with median, 25th and 75th percentile and Tukey whiskers (± 
1.5 times interquartile range). Control vs. PXE: * p≤0.05; ns p>0.05. Cohorts <45 years (n=23) vs. cohorts 
>45 years (n=22): ns p>0.05.  
As IGFBP3 showed aberrant protein concentrations 
in PXE sera, we performed qPCR analysis for 
determination of gene expression in PXE fibroblasts 
compared to NHDF. As seen in Fig. 4A, PXE fibroblasts 
showed a significant decrease in IGFBP3 mRNA 
expression compared to NHDF (PXE: 1.24 ± 0.29; 
control: 3.03 ± 0.70; p≤0.05). We further showed a 
decrease of IGFBP3 protein concentration in supernatants 
of PXE fibroblasts compared to NHDF which did not 
reach statistical significance (Fig 4B). This was mainly 
due to potential gender specific variations. As seen in Fig. 
5A-B, IGFBP3 mRNA expression as well as protein 
concentration of supernatant showed no differences in 
PXE fibroblasts compared to NHDF for females. In 
contrast to this, IGFBP3 mRNA expression (PXE: 1.42 ± 
0.37; control: 4.23 ± 0.94; p≤0.01) and protein 
concentration of supernatants (PXE: 8.0 ± 1.9 
[ng/mL]/µgDNA; control: 23.4 ± 1.9 [ng/mL]/µgDNA; 
p≤0.01) were significantly decreased in PXE fibroblasts 




PXE is a rare inherited genetic disorder mainly caused by 
mutations in the ABCC6 gene [5, 6]. By now, PXE 
pathogenesis has just barely been discussed in the view of 
the fact that the clinical and molecular characteristics of 
PXE patients equal those seen in premature aging and 
premature aging syndromes. Thus, this study was 
performed to evaluate specific aging biomarkers in sera 
and fibroblasts from PXE patients to get insights into 
potential aging processes associated with an ABCC6 
deficiency in PXE patients.  
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Figure 4. Local IGFBP3 mRNA expression and protein concentration. (A) Relative IGFBP3 mRNA expression of PXE fibroblasts 
(grey) and NHDF (white). (B) IGFBP3 protein concentration in supernatant of PXE fibroblasts (grey) and NHDF (white). Data are 
shown as mean ± SEM. Control vs. PXE: * p≤0.05; ns p>0.05.  
The first biomarker analyzed is CCL11. CCL11 is a 
chemokine, acting as a chemoattractant for eosinophils 
and plays a role in arteriosclerosis, inflammation and 
neurogenesis [29, 34, 35]. We found significantly 
increased serum concentrations of CCL11 with age in 
both, PXE patients and healthy controls. This is in 
accordance with previous studies showing an increase of 
serum CCL11 concentration with age [34, 36]. 
Furthermore, our study showed no significant differences 
in CCL11 serum concentrations between PXE patients 
and healthy controls. Elevated CCL11 serum 
concentrations are associated with different stages of age-
related macular degeneration (AMD), except for 
neovascular AMD. Patients with neovascular AMD 
showed, like PXE patients in our study, normal CCL11 
serum concentrations compared to healthy controls [37]. 
This matches the fact that the vision impairments of PXE 
patients show similarities like choroidal 
neovascularization (CNV) with neovascular AMD [7, 38-
40].  
Another intensively discussed aging biomarker is 
GDF11, a member of the transforming growth factor-β 
superfamily and closely related to myostatin (GDF8). 
GDF11 plays a role in mammalian development and was 
claimed to have anti-aging effects [22, 24, 41]. We have 
seen a minor decrease in GDF11 serum concentrations 
with age and between PXE and healthy controls, though 
these changes did not reach statistical significance. 
Previous studies investigating age dependent GDF11 
blood level showed controversial results possibly due to 
specifity and selectivity of detection methods and to 
potential low overall GDF11 serum concentration [24, 33, 
42-44]. Although, there was not always strictly 
distinguished between GDF8 and GDF11, some studies 
reported an overall decrease of GDF11 or GDF11/8 
concentrations in the bloodstream with increasing age [24, 
44]. Loffredo et al. showed a reduction in GDF11 serum 
concentrations and proved that recombinant GDF11 can 
reverse age-related cardiac hypertrophy in mice [24]. In 
2015, a study by Olsen et al. confirmed this by linking 
decreasing GDF11/8 levels to higher risks of 
cardiovascular events and death [45]. As we could not 
detect any significant changes in GDF11 serum 
concentrations for PXE patients, it could be suggested that 
circulating GDF11 plays only a minor role in PXE or age-
related pathogenesis going along with it. These 
ambiguous results rather raised the question whether local 
and not systemic GDF11 concentrations are relevant in 
PXE. We, therefore, measured GDF11 mRNA expression 
in human dermal fibroblasts from PXE patients as well as 
in NHDF and found a significant reduction in mRNA 
expression in PXE fibroblasts compared to NHDF. 
Unfortunately, determination of GDF11 levels in cell 
culture supernatants was not possible due to low protein 
concentrations. However, previous studies showed a 
decreased GDF11 mRNA and protein expression in 
spleen could be associated with age in mice [24]. It was 
proposed that GDF11 expression in spleen is rather high 
compared to other tissues and may primarily contribute to 
circulating GDF11 concentrations [24]. Thus, the 
decreased GDF11 mRNA expression in PXE fibroblasts 
do not necessarily correlate with detected circulating 
GDF11 levels. This probably strengthen the assumption 
that autocrine or paracrine effects of aberrant locally 
expressed GDF11 levels could be more important for PXE 
pathogenesis in affected tissues than circulating GDF11.  
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Figure 5. Male and female specific IGFBP3 mRNA expression and protein concentration. (A) Relative 
IGFBP3 mRNA expression of female PXE fibroblasts (grey) and NHDF (white). (B) IGFBP3 protein 
concentration in supernatant of female PXE fibroblasts (grey) and NHDF (white). (C) Relative IGFBP3 mRNA 
expression of male PXE fibroblasts (grey) and NHDF (white). (D) IGFBP3 protein concentration in supernatant 
of male PXE fibroblasts (grey) and NHDF (white). Data are shown as mean ± SEM. Control vs. PXE: ** p≤0.01; 
ns p>0.05.  
 
A third protein which is closely associated with aging 
is IGF1. IGF1 plays a wide role in proliferation and tissue 
growth and is known as an anti-aging factor ([30], 
reviewed in [46]). IGF1 serum levels peak in young 
adolescents and subsequently declines with age [47]. 
Studies showed that progeroid Zmpste24-/- mice have a 
disturbed IGF1/growth hormone (GH) ratio with low 
IGF1 plasma concentrations. Application of recombinant 
IGF1, normalized IGF1/GH ratio and extended the 
lifespan of Zmpste24-/- mice [30]. 
Measuring total serum IGF1 concentrations in PXE 
patients and controls, we found no statistical significant 
changes with age as the variances of individuals in each 
group may mask the expected age associated decline of 
total IGF1 levels. Apart from this no significant 
differences were seen between PXE and control cohorts. 
As the main source for circulating IGF1 is the liver [48] 
direct effects of ABCC6 deficiency on expression and 
secretion of it are unlikely. 
The majority of circulating IGF1 is bound to IGFBP3 
which strictly controls IGF1 availability (reviewed in 
[49]). Additionally, studies showed an increase in 
IGFBP3 expression in old NHDF as well as in senescent 
human umbilical vein endothelial cells compared to 
young non senescent cells [28, 50]. We found that 
IGFBP3 serum levels in PXE and control sera showed no 
significant difference with age, but a significant increase 
in PXE patients over 45 years compared to the appropriate 
control cohort. By calculating the molar IGF1/IGFBP3 
ratio it could be suggested that less circulating free IGF1 
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is present in PXE patients over 45 years compared to 
healthy controls. This possibly results in a reduced IGF1 
signaling in peripheral tissues which supports the 
hypothesis of an accelerated aging process in PXE 
patients.  
In addition, studies also showed that locally 
expressed IGFBP3 may have paracrine or autocrine 
effects on tissue specific IGF1 signaling as local IGFBP3 
expression can differ from circulating serum 
concentrations [51]. We measured IGFBP3 mRNA 
expression and protein concentration in supernatants of 
primary human dermal fibroblasts of PXE patients and 
healthy controls to evaluate tissue specific IGFBP3 
expression. Both, mRNA expression and protein analysis 
showed an overall decrease in PXE fibroblasts compared 
to NHDF. Interestingly, mRNA expression and protein 
concentrations in supernatants showed opposed results in 
males and females with decreased expression in males and 
no changes for females. One has to mention that the 
fibroblasts from male PXE donors are derived from 
different skin areas as the control fibroblasts and the 
fibroblasts from the female PXE donor. Thus, instead of 
gender associated reasons, the observed opposed results 
could, thus, be also derived from different expression 
patterns due to the biopsy source. Nevertheless, results 
from Oliver et al. support the gender specific expression 
of IGFBP3 as they showed decreased IGFBP3 protein 
expression in male and even no change of protein 
expression in female IGF1 overexpressing skeletal muscle 
of old mice compared to younger ones [51]. They also 
showed that this sexual dimorphism was not due to a 
different response to locally overexpressed IGF1 but to 
alternative age and gender dependent factors [51]. 
Contrary to their results, we did not only see differences 
in protein concentration but also distinct mRNA 
expression between genders which could be related to 
tissue specific regulation. Thus, we see a decreased 
IGFBP3 mRNA expression in PXE fibroblasts of males 
and no significant changes in female PXE fibroblasts 
compared to NHDF. A study of Lovqist et al. showed 
increased IGFBP3 mRNA expression in retinal 
vasculature under conditions of hypoxia [52]. They 
assumed a protective function of IGFBP3 contributed to 
the prevention of oxygen-induced vessel loss and 
abnormal neovascularization [52]. Low tissue specific 
IGFBP3 concentrations could, possibly, promote CNV 
when also found in retinal tissue. CNV is a prominent 
clinical manifestation seen in PXE patients [7, 8, 39]. 
Surprisingly, the observed sexual dimorphism showed 
only low tissue specific IGFBP3 expression in males 
although it is often reported that females are 
predominantly affected by PXE [7]. At first sight, the 
results for tissue specific expression did not match the 
results obtained by the measurement of serum IGFBP3 
levels showing increased IGFBP3 concentrations for PXE 
patients compared to healthy controls. As far more 
females than males were tested for IGFBP3 serum levels 
this may explain why an increase rather than a decrease 
was seen for IGFBP3 serum concentrations. Additionally, 
the other tested biomarkers showed no gender specific 
expression patterns which demonstrated that this potential 
sexual dimorphism probably only applies for selected 
targets and is not a general phenomenon.   
Nevertheless, our results show that ABCC6 
deficiency may lead to aberrant IGFBP3 mRNA and 
protein expression in PXE fibroblasts associated with 
potential gender specific aging processes, again, 
strengthen the assumption of an accelerated aging process 
in PXE patients. Furthermore, it underlines that an 
ABCC6 deficiency has a direct influence on affected 
peripheral tissues.         
This is the first study linking ABCC6 deficiency to 
aberrant systemic and especially local concentrations of 
aging biomarkers in peripheral tissues. These findings 
could be associated with a potential premature aging 
process in PXE patients and particularly in affected 
peripheral tissues. As a result of this, it should be 
considered that clinical manifestation seen in PXE 
patients, like visual impairments or soft tissue 
calcification which are, thusfar, claimed to be direct 
results of aberrant concentrations of the unknown ABCC6 
substrate, could also be indirect consequences caused by 
premature aging processes induced by e.g. an aberrant 
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